NK-252

Item no.	HY-19734-10mg
Manufacturer	MedChem Express
CASRN	1414963-82-8
Amount	10 mg
Quantity options	100 mg 10mM/1mL 10 mg 25 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer
Type	Inhibitors
Specific against	other
Purity	99.93
Formula	C13H11N5O3
Citations	[1]Shimozono R et al. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. Mol Pharmacol. 2013 Jul, 84(1):62-70.<br/>[2]Kiue A, et al. Enhancement of antitumour activity of etoposide by dihydropyridines on drug-sensitive and drug-resistant leukaemia in mice. Br J Cancer. 1991 Aug;64(2):221-6.
Smiles	O=C(NCC1=NC=CC=C1)NC2=NN=C(C3=CC=CO3)O2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1414963-82-8
Available
Product Description	NK-252 is a potential Nrf2 activator, which exhibits a great Nrf2-activating potential.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	285.26
Clinical Information	No Development Reported
Manufacturers Research Area	Cancer
Solubility	DMSO : ≥ 29 mg/mL
Target	Keap1-Nrf2
Manufacturers Target	Keap1-Nrf2
Manufacturers Pathway	NF-κB
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-19734-10mg-safety-datasheet.pdf